Elraglusib by Actuate Therapeutics for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF): Likelihood of Approval

Elraglusib is under clinical development by Actuate Therapeutics and currently in Phase II for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF).

Smartaly, Ambiq to Develop AI-Powered, Week-Long ECG Monitor

What You Should Know: – Ambiq, a leader in low-power semiconductors, and Smartaly, an electronics design firm, have partnered to create an artificial intelligence (AI)

March 20, 2024

Stanford researchers uncover key to overcoming chemoresistance in pancreatic cancer

Pancreatic cancer is a particularly aggressive and difficult-to-treat cancer, in part because it is often resistant to chemotherapy.

July 5, 2024

Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology – Biotech Investments

Issuer: Mainz BioMed N.V. / Key word(s): Conference/Study results 27.09.2023 / 14:01 CET/CEST The issuer is solely responsible for the content of this announcement. Mainz

September 28, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.